As the cliché goes, ''there's no I in team sports.'' The goal of every sports organization is to assemble a team that brings players with complementary skills together to capitalize on their strengths while minimizing their weaknesses. Successful sports franchises are often said to have good ''chemistry,'' referring to an ability to meld diverse individual strengths such that team performance rises above individual contributions. In this issue of Cell, Finan and colleagues adopt a similar strategy to create a ''hormone team'' consisting of covalently linked glucagon and triiodothyronine (thyroid hormone T3 or T3) (Finan et al., 2016) . These unlikely teammates, when brought together, create a remarkable compound that improves key metabolic parameters in mouse models of metabolic syndrome.
In metabolic disease, most drugs target individual symptoms, such as glucose tolerance (Aschner et al., 2006) or dyslipidemia (Goldstein and Brown, 2015) . Finan and co-workers ambitiously sought to develop a single therapeutic entity capable of addressing several metabolic disease symptoms and reversing obesity. Individually, glucagon (Finan et al., 2015) and the thyroid hormone T3 (Zhang and Lazar, 2000) lower lipid levels and promote weight loss, making these hormones exceptional candidates for treating metabolic disease; however, as monotherapies, they also have deleterious effects that limit their therapeutic potential. Thyroid hormone T3 lowers serum cholesterol and lipoprotein levels and increases adipose tissue energy expenditure, but these beneficial attributes are accompanied by increased food intake, an elevated heart rate, cardiac hypertrophy, muscle wasting, and bone loss (Gardner and Shoback, 2011) . Glucagon also displays productive activities, such as the lowering of triglycerides and promoting weight loss, but these are accompanied by increases in liver gluconeogenesis leading to detrimental hyperglycemia (Gardner and Shoback, 2011) .
Previous work has shown that the coordinated activation of multiple hormone pathways could abrogate the hyperglycemic effects of glucagon, illuminating a potential way to separate its negative and positive effects. Specifically, a synthetic peptide triagonist that activates the GLP-1, GIP, and glucagon receptors successfully captured the beneficial weight loss and lipid-lowering effects of glucagon while suppressing hyperglycemia through activation of incretin-based glucoselowering pathways (Finan et al., 2015) .
Capitalizing on the beneficial effects of glucagon and T3 takes a next step by combining the glucagon peptide with the T3 small molecule (Figure 1) . By covalently linking these two hormones to create the hybrid synthetic agent glucagon/T3, Finan et al. directed T3 to tissues expressing the glucagon receptor, such as the liver and adipose tissue, and avoided T3 accumulation in muscle and bone, where the thyroid hormone has detrimental effects. Moreover, by increasing T3 content in the liver, this hybrid hormone proved capable of suppressing the gluconeogenic properties of glucagon. This combination of two hormones enables counter-suppression of their individual adverse effects, while maintaining their beneficial properties.
The potential clinical benefit of glucagon/T3 was shown in a mouse model of heart disease where this agent reversed arterial plaque formation, consistent with its effect on lowering plasma cholesterol and triglycerides, as well as hepatic lipids. Furthermore, glucagon/T3 reversed fat accumulation and fibrosis in animal models of fatty liver, a condition that currently lacks effective therapeutics. Adding to these effects, the potential to overcome hyperglycemia associated with glucagon monotherapy, as evidenced in the current study, Glucagon/T3 has a combined set of pharmacological properties that have been difficult to achieve with other single agent therapies.
The activities of glucagon/T3 require the glucagon receptor, and glucagon/T3 induced stronger gene expression changes in the liver than T3 alone, likely reflecting the higher liver T3 concentrations achieved with the hybrid molecule through its binding to the receptor. These gene expression studies also identified many genes that were altered by glucagon/T3, but not by T3 or glucagon alone, pointing to potential synergistic effects specific to the dual-acting single agent. One gene highly elevated in adipose tissue by glucagon/T3 was uncoupling protein 1 (UCP1), a mitochondrial protein that increases energy expenditure to facilitate thermogenesis (Feldmann et al., 2009) . Studies with UCP1 null mice demonstrated that UCP1 is necessary for the observed weight loss and energy expenditure effects of glucagon/T3, suggesting that glucagon/T3 has the ability to promote the browning of white fat (Boströ m et al., 2012) . Lastly, chronic glucagon/T3 treatment did not produce bone loss or cardiac hypertrophy unlike T3 alone (Gardner and Shoback, 2011 ). These differences may reflect the minimal global tissue exposure of glucagon/T3, which instead is preferentially directed to liver via the glucagon receptor.
Characterization of Glucagon/T3, as well as previous work on hormone conjugates (Finan et al., 2012) , highlights the power of chemically-fused hormone combinations as a means to control endocrine signaling to maximize therapeutic benefits and minimize adverse effects. The successful demonstration of this concept should prime new efforts toward the synthesis of additional conjugates as candidate therapeutics to treat a variety of diseases. The glucagon/T3 agent demonstrates that such hormone conjugates need not be limited to combinations of peptides, but can also utilize other biologically active molecules, including small-molecule hormones, vitamins, and even synthetic compounds to modulate drug activity and safety.
The structure of glucagon/T3 contains glucagon, a C-terminal peptide linker, and T3 connected through a lysine side chain by a spacer (Figure 1) . Inactive variants of this molecule with a different linker region or an inactive thyroid hormone analog were used as negative controls throughout the study, which underscores one important attribute of synthetic hormones-routes for their production also often provide access to structural variants that lack biological activity for use as pharmacological controls.
The most important concept to emerge from this work, however, might be the value of drugs that can engage more than one molecular target and pathway to treat complex multifactorial diseases. A key to the success of such tailored polypharmacology agents may be the homing of their activity to specific subsets of organs, where their action is beneficial, and avoiding crosstalk with other anatomical sites of potential risk. Glucagon/T3 thus represents an ambitious effort in drug design that seeks to treat symptoms of and reverse the underlying cause of metabolic disease by harnessing the combined action of two hormones with the right ''chemistry'' and biology to create a championship caliber preclinical compound. As monotherapies these hormones also produce deleterious effects, including hyperglycemia for glucagon and cardiomyopathy and bone loss for T3. Finan et. al. synthesized glucagon/T3, a covalent peptide-small molecule fusion of glucagon and T3, that retains the beneficial characteristics of these individual hormones while avoiding negative side effects.
